0001104659-23-128788.txt : 20231222
0001104659-23-128788.hdr.sgml : 20231222
20231222160523
ACCESSION NUMBER: 0001104659-23-128788
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231220
FILED AS OF DATE: 20231222
DATE AS OF CHANGE: 20231222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jin David
CENTRAL INDEX KEY: 0001930732
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35366
FILM NUMBER: 231509771
MAIL ADDRESS:
STREET 1: C/O AVENUE THERAPEUTICS, INC.
STREET 2: 1140 AVENUE OF THE AMERICAS, FLOOR 9
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fortress Biotech, Inc.
CENTRAL INDEX KEY: 0001429260
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 205157386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 1111 KANE CONCOURSE
STREET 2: SUITE 301
CITY: BAY HARBOR ISLANDS
STATE: FL
ZIP: 33154
FORMER COMPANY:
FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC
DATE OF NAME CHANGE: 20080310
4
1
tm2333573-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-12-20
0
0001429260
Fortress Biotech, Inc.
FBIO
0001930732
Jin David
C/O FORTRESS BIOTECH, INC.
1111 KANE CONCOURSE SUITE 301
BAY HARBOR ISLANDS
FL
33154
0
1
0
0
Chief Financial Officer
0
COMMON STOCK, PAR VALUE $0.001
2023-12-20
4
A
0
140000
0.00
A
235916
D
Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split.
Represents an award of 140,000 restricted stock units which will vest in 16 equal quarterly installments after the grant date, December 20, 2023. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.
Total holdings include 230,000 shares underlying deferred restricted stock units.
/s/ David Jin
2023-12-22